---
document_datetime: 2025-12-29 11:50:56
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/nexavar.html
document_name: nexavar.html
version: success
processing_time: 0.1277949
conversion_datetime: 2025-12-30 10:24:52.72097
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Nexavar

[RSS](/en/individual-human-medicine.xml/66215)

##### Authorised

This medicine is authorised for use in the European Union

sorafenib Medicine Human Authorised

On Monday, 12 January 2026, between 07:00 and 10:00 CET (Amsterdam time), this website will be unavailable due to scheduled maintenance.

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Nexavar](#news-on)
- [Product information - with tracked changes](#product-information-with-tracked-changes-75509)
- [More information on Nexavar](#more-information-on-nexavar-642)
- [More information on Nexavar](#related-medicines)
- [Topics](#topics)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

This is a summary of the European public assessment report (EPAR) for Nexavar. It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Nexavar.

Expand section

Collapse section

## What is Nexavar?

Nexavar is a cancer medicine that contains the active substance sorafenib. It is available as tablets (200 mg).

## What is Nexavar used for?

Nexavar is used to treat patients who have the following diseases:

- hepatocellular carcinoma (a type of liver cancer);
- advanced renal cell carcinoma (a type of kidney cancer) when anticancer treatment with interferon alfa or interleukin 2 has failed or cannot be used;
- differentiated thyroid carcinoma (a type of cancer originating from the follicular cells of the thyroid gland) when the cancer has progressed or spread locally or to other parts of the body and does not respond to treatment with radioactive iodine.

Because the numbers of patients with these diseases are low, the diseases are considered 'rare', and Nexavar was designated an 'orphan medicine' (a medicine used in rare diseases).

The medicine can only be obtained with a prescription.

## How is Nexavar used?

Treatment with Nexavar should be supervised by doctors who have experience of anticancer treatments.

Nexavar is given as two tablets twice a day, without food or with a meal that is low in fat. The treatment is continued as long as the patient continues to benefit from it without too many side effects. To manage side effects, treatment may have to be temporarily interrupted or the dose may be reduced.

## How does Nexavar work?

The active substance in Nexavar, sorafenib, is a protein kinase inhibitor. This means that it blocks some specific enzymes known as protein kinases. These enzymes can be found in some receptors on the surface of cancer cells, where they are involved in the growth and spread of cancer cells, and in the blood vessels that supply the tumours, where they are involved in the development of new blood vessels. By blocking these enzymes, Nexavar can reduce the growth of cancer cells and cut off the blood supply that keeps cancer cells growing.

## How has Nexavar been studied?

Nexavar has been compared with placebo (a dummy treatment) in three main studies. The first study involved 602 patients with hepatocellular carcinoma; the second involved 903 patients with advanced renal cell carcinoma in whom one previous anticancer treatment had stopped working; and the third study involved 417 patients with differentiated thyroid carcinoma that had progressed or spread locally or to other parts of the body and did not respond to treatment with radioactive iodine. The main measures of effectiveness were how long the patients survived or how long the patients lived without their disease getting worse.

## What benefit has Nexavar shown during the studies?

Nexavar was more effective than placebo in increasing how long the patients survived or how long the patients lived without their disease getting worse.

In the study of hepatocellular carcinoma, the patients taking Nexavar survived for an average of 10.7 months, compared with 7.9 months in those taking placebo.

In the study of renal cell carcinoma, the patients taking Nexavar survived for an average of 19.3 months, compared with 15.9 months in those taking placebo. This finding was based on the results from all 903 patients, including about 200 who had switched from placebo to Nexavar before the end of the study. The patients taking Nexavar lived for longer without their disease getting worse (167 days, around five and a half months) than those who took placebo (84 days, around three months). This finding was based on the results from 769 patients.

In the study in differentiated thyroid carcinoma, the patients taking Nexavar lived for an average of 10.8 months without their disease getting worse, compared with 5.8 months in those taking placebo.

## What is the risk associated with Nexavar?

The most common side effects with Nexavar are diarrhoea, rash, alopecia (hair loss), infection, hand foot skin reaction (rash and pain on the palms of the hands and soles of the feet) and fatigue (tiredness). The most important serious side effects are myocardial infarction (heart attack) or ischaemia (reduced oxygen supply to the heart), gastrointestinal perforation (a hole that develops in the wall of the gut), drug-induced hepatitis (a disease of the liver), haemorrhage (bleeding) and hypertension or hypertensive crisis (high blood pressure).

For the full list of all side effects and restrictions with Nexavar, see the package leaflet.

## Why has Nexavar been approved?

The CHMP decided that Nexavar's benefits are greater than its risks and recommended that it be given marketing authorisation.

## Other information about Nexavar

The European Commission granted a marketing authorisation valid throughout the European Union for Nexavar on 19 July 2006.

For more information about treatment with Nexavar, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.

Nexavar : EPAR - Summary for the public

Reference Number: EMA/391638/2011

English (EN) (82.51 KB - PDF)

**First published:** 18/05/2009

**Last updated:** 18/06/2014

[View](/en/documents/overview/nexavar-epar-summary-public_en.pdf)

[Other languages (22)](#file-language-dropdown-973)

български (BG) (109.84 KB - PDF)

**First published:**

18/05/2009

**Last updated:**

18/06/2014

[View](/bg/documents/overview/nexavar-epar-summary-public_bg.pdf)

español (ES) (105 KB - PDF)

**First published:**

18/05/2009

**Last updated:**

18/06/2014

[View](/es/documents/overview/nexavar-epar-summary-public_es.pdf)

čeština (CS) (131.74 KB - PDF)

**First published:**

18/05/2009

**Last updated:**

18/06/2014

[View](/cs/documents/overview/nexavar-epar-summary-public_cs.pdf)

dansk (DA) (103.7 KB - PDF)

**First published:**

18/05/2009

**Last updated:**

18/06/2014

[View](/da/documents/overview/nexavar-epar-summary-public_da.pdf)

Deutsch (DE) (104.75 KB - PDF)

**First published:**

18/05/2009

**Last updated:**

18/06/2014

[View](/de/documents/overview/nexavar-epar-summary-public_de.pdf)

eesti keel (ET) (103.89 KB - PDF)

**First published:**

18/05/2009

**Last updated:**

18/06/2014

[View](/et/documents/overview/nexavar-epar-summary-public_et.pdf)

ελληνικά (EL) (133.63 KB - PDF)

**First published:**

18/05/2009

**Last updated:**

18/06/2014

[View](/el/documents/overview/nexavar-epar-summary-public_el.pdf)

français (FR) (106.19 KB - PDF)

**First published:**

18/05/2009

**Last updated:**

18/06/2014

[View](/fr/documents/overview/nexavar-epar-summary-public_fr.pdf)

hrvatski (HR) (98.59 KB - PDF)

**First published:**

18/05/2009

**Last updated:**

18/06/2014

[View](/hr/documents/overview/nexavar-epar-summary-public_hr.pdf)

italiano (IT) (104.38 KB - PDF)

**First published:**

18/05/2009

**Last updated:**

18/06/2014

[View](/it/documents/overview/nexavar-epar-summary-public_it.pdf)

latviešu valoda (LV) (128.65 KB - PDF)

**First published:**

18/05/2009

**Last updated:**

18/06/2014

[View](/lv/documents/overview/nexavar-epar-summary-public_lv.pdf)

lietuvių kalba (LT) (128.74 KB - PDF)

**First published:**

18/05/2009

**Last updated:**

18/06/2014

[View](/lt/documents/overview/nexavar-epar-summary-public_lt.pdf)

magyar (HU) (126.42 KB - PDF)

**First published:**

18/05/2009

**Last updated:**

18/06/2014

[View](/hu/documents/overview/nexavar-epar-summary-public_hu.pdf)

Malti (MT) (195.76 KB - PDF)

**First published:**

18/05/2009

**Last updated:**

18/06/2014

[View](/mt/documents/overview/nexavar-epar-summary-public_mt.pdf)

Nederlands (NL) (103.81 KB - PDF)

**First published:**

18/05/2009

**Last updated:**

18/06/2014

[View](/nl/documents/overview/nexavar-epar-summary-public_nl.pdf)

polski (PL) (131.45 KB - PDF)

**First published:**

18/05/2009

**Last updated:**

18/06/2014

[View](/pl/documents/overview/nexavar-epar-summary-public_pl.pdf)

português (PT) (104.21 KB - PDF)

**First published:**

18/05/2009

**Last updated:**

18/06/2014

[View](/pt/documents/overview/nexavar-epar-summary-public_pt.pdf)

română (RO) (128.96 KB - PDF)

**First published:**

18/05/2009

**Last updated:**

18/06/2014

[View](/ro/documents/overview/nexavar-epar-summary-public_ro.pdf)

slovenčina (SK) (130.78 KB - PDF)

**First published:**

18/05/2009

**Last updated:**

18/06/2014

[View](/sk/documents/overview/nexavar-epar-summary-public_sk.pdf)

slovenščina (SL) (121.62 KB - PDF)

**First published:**

18/05/2009

**Last updated:**

18/06/2014

[View](/sl/documents/overview/nexavar-epar-summary-public_sl.pdf)

Suomi (FI) (103.31 KB - PDF)

**First published:**

18/05/2009

**Last updated:**

18/06/2014

[View](/fi/documents/overview/nexavar-epar-summary-public_fi.pdf)

svenska (SV) (103.96 KB - PDF)

**First published:**

18/05/2009

**Last updated:**

18/06/2014

[View](/sv/documents/overview/nexavar-epar-summary-public_sv.pdf)

Nexavar : EPAR - Risk Management Plan

English (EN) (984.77 KB - PDF)

**First published:** 06/12/2022

**Last updated:** 28/03/2025

[View](/en/documents/rmp/nexavar-epar-risk-management-plan_en.pdf)

## Product information

Nexavar : EPAR - Product information

English (EN) (490.5 KB - PDF)

**First published:** 22/12/2009

**Last updated:** 28/03/2025

[View](/en/documents/product-information/nexavar-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-81)

български (BG) (583 KB - PDF)

**First published:**

22/12/2009

**Last updated:**

28/03/2025

[View](/bg/documents/product-information/nexavar-epar-product-information_bg.pdf)

español (ES) (554.44 KB - PDF)

**First published:**

22/12/2009

**Last updated:**

28/03/2025

[View](/es/documents/product-information/nexavar-epar-product-information_es.pdf)

čeština (CS) (579.3 KB - PDF)

**First published:**

22/12/2009

**Last updated:**

28/03/2025

[View](/cs/documents/product-information/nexavar-epar-product-information_cs.pdf)

dansk (DA) (490.78 KB - PDF)

**First published:**

22/12/2009

**Last updated:**

28/03/2025

[View](/da/documents/product-information/nexavar-epar-product-information_da.pdf)

Deutsch (DE) (544.59 KB - PDF)

**First published:**

22/12/2009

**Last updated:**

28/03/2025

[View](/de/documents/product-information/nexavar-epar-product-information_de.pdf)

eesti keel (ET) (561.94 KB - PDF)

**First published:**

22/12/2009

**Last updated:**

28/03/2025

[View](/et/documents/product-information/nexavar-epar-product-information_et.pdf)

ελληνικά (EL) (585.43 KB - PDF)

**First published:**

22/12/2009

**Last updated:**

28/03/2025

[View](/el/documents/product-information/nexavar-epar-product-information_el.pdf)

français (FR) (576.21 KB - PDF)

**First published:**

22/12/2009

**Last updated:**

28/03/2025

[View](/fr/documents/product-information/nexavar-epar-product-information_fr.pdf)

hrvatski (HR) (586.81 KB - PDF)

**First published:**

22/12/2009

**Last updated:**

28/03/2025

[View](/hr/documents/product-information/nexavar-epar-product-information_hr.pdf)

íslenska (IS) (516.39 KB - PDF)

**First published:**

22/12/2009

**Last updated:**

28/03/2025

[View](/is/documents/product-information/nexavar-epar-product-information_is.pdf)

italiano (IT) (500.16 KB - PDF)

**First published:**

22/12/2009

**Last updated:**

28/03/2025

[View](/it/documents/product-information/nexavar-epar-product-information_it.pdf)

latviešu valoda (LV) (604.37 KB - PDF)

**First published:**

22/12/2009

**Last updated:**

28/03/2025

[View](/lv/documents/product-information/nexavar-epar-product-information_lv.pdf)

lietuvių kalba (LT) (592.7 KB - PDF)

**First published:**

22/12/2009

**Last updated:**

28/03/2025

[View](/lt/documents/product-information/nexavar-epar-product-information_lt.pdf)

magyar (HU) (565.84 KB - PDF)

**First published:**

22/12/2009

**Last updated:**

28/03/2025

[View](/hu/documents/product-information/nexavar-epar-product-information_hu.pdf)

Malti (MT) (619.61 KB - PDF)

**First published:**

22/12/2009

**Last updated:**

28/03/2025

[View](/mt/documents/product-information/nexavar-epar-product-information_mt.pdf)

Nederlands (NL) (530.01 KB - PDF)

**First published:**

22/12/2009

**Last updated:**

28/03/2025

[View](/nl/documents/product-information/nexavar-epar-product-information_nl.pdf)

norsk (NO) (492.02 KB - PDF)

**First published:**

22/12/2009

**Last updated:**

28/03/2025

[View](/no/documents/product-information/nexavar-epar-product-information_no.pdf)

polski (PL) (573.77 KB - PDF)

**First published:**

22/12/2009

**Last updated:**

28/03/2025

[View](/pl/documents/product-information/nexavar-epar-product-information_pl.pdf)

português (PT) (503.53 KB - PDF)

**First published:**

22/12/2009

**Last updated:**

28/03/2025

[View](/pt/documents/product-information/nexavar-epar-product-information_pt.pdf)

română (RO) (610.67 KB - PDF)

**First published:**

22/12/2009

**Last updated:**

28/03/2025

[View](/ro/documents/product-information/nexavar-epar-product-information_ro.pdf)

slovenčina (SK) (585.15 KB - PDF)

**First published:**

22/12/2009

**Last updated:**

28/03/2025

[View](/sk/documents/product-information/nexavar-epar-product-information_sk.pdf)

slovenščina (SL) (592.52 KB - PDF)

**First published:**

22/12/2009

**Last updated:**

28/03/2025

[View](/sl/documents/product-information/nexavar-epar-product-information_sl.pdf)

Suomi (FI) (515 KB - PDF)

**First published:**

22/12/2009

**Last updated:**

28/03/2025

[View](/fi/documents/product-information/nexavar-epar-product-information_fi.pdf)

svenska (SV) (523.91 KB - PDF)

**First published:**

22/12/2009

**Last updated:**

28/03/2025

[View](/sv/documents/product-information/nexavar-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** II/0059 13/02/2025

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Nexavar : EPAR - All Authorised presentations

English (EN) (10.1 KB - PDF)

**First published:** 05/03/2007

**Last updated:** 05/03/2007

[View](/en/documents/all-authorised-presentations/nexavar-epar-all-authorised-presentations_en.pdf)

[Other languages (18)](#file-language-dropdown-171)

español (ES) (10.69 KB - PDF)

**First published:**

05/03/2007

**Last updated:**

05/03/2007

[View](/es/documents/all-authorised-presentations/nexavar-epar-all-authorised-presentations_es.pdf)

čeština (CS) (39.64 KB - PDF)

**First published:**

05/03/2007

**Last updated:**

05/03/2007

[View](/cs/documents/all-authorised-presentations/nexavar-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (10.33 KB - PDF)

**First published:**

05/03/2007

**Last updated:**

05/03/2007

[View](/da/documents/all-authorised-presentations/nexavar-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (10.27 KB - PDF)

**First published:**

05/03/2007

**Last updated:**

05/03/2007

[View](/de/documents/all-authorised-presentations/nexavar-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (10.68 KB - PDF)

**First published:**

05/03/2007

**Last updated:**

05/03/2007

[View](/et/documents/all-authorised-presentations/nexavar-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (73.57 KB - PDF)

**First published:**

05/03/2007

**Last updated:**

05/03/2007

[View](/el/documents/all-authorised-presentations/nexavar-epar-all-authorised-presentations_el.pdf)

français (FR) (10.58 KB - PDF)

**First published:**

05/03/2007

**Last updated:**

05/03/2007

[View](/fr/documents/all-authorised-presentations/nexavar-epar-all-authorised-presentations_fr.pdf)

italiano (IT) (10.12 KB - PDF)

**First published:**

05/03/2007

**Last updated:**

05/03/2007

[View](/it/documents/all-authorised-presentations/nexavar-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (74.26 KB - PDF)

**First published:**

05/03/2007

**Last updated:**

05/03/2007

[View](/lv/documents/all-authorised-presentations/nexavar-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (74.71 KB - PDF)

**First published:**

05/03/2007

**Last updated:**

05/03/2007

[View](/lt/documents/all-authorised-presentations/nexavar-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (75.65 KB - PDF)

**First published:**

05/03/2007

**Last updated:**

05/03/2007

[View](/hu/documents/all-authorised-presentations/nexavar-epar-all-authorised-presentations_hu.pdf)

Nederlands (NL) (10.02 KB - PDF)

**First published:**

05/03/2007

**Last updated:**

05/03/2007

[View](/nl/documents/all-authorised-presentations/nexavar-epar-all-authorised-presentations_nl.pdf)

polski (PL) (41.68 KB - PDF)

**First published:**

05/03/2007

**Last updated:**

05/03/2007

[View](/pl/documents/all-authorised-presentations/nexavar-epar-all-authorised-presentations_pl.pdf)

português (PT) (10.66 KB - PDF)

**First published:**

05/03/2007

**Last updated:**

05/03/2007

[View](/pt/documents/all-authorised-presentations/nexavar-epar-all-authorised-presentations_pt.pdf)

slovenčina (SK) (39.59 KB - PDF)

**First published:**

05/03/2007

**Last updated:**

05/03/2007

[View](/sk/documents/all-authorised-presentations/nexavar-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (10.22 KB - PDF)

**First published:**

05/03/2007

**Last updated:**

05/03/2007

[View](/sl/documents/all-authorised-presentations/nexavar-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (10.46 KB - PDF)

**First published:**

05/03/2007

**Last updated:**

05/03/2007

[View](/fi/documents/all-authorised-presentations/nexavar-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (10.35 KB - PDF)

**First published:**

05/03/2007

**Last updated:**

05/03/2007

[View](/sv/documents/all-authorised-presentations/nexavar-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Nexavar Active substance sorafenib International non-proprietary name (INN) or common name sorafenib Therapeutic area (MeSH)

- Carcinoma, Hepatocellular
- Carcinoma, Renal Cell

Anatomical therapeutic chemical (ATC) code L01EX02

### Pharmacotherapeutic group

Antineoplastic agents

### Therapeutic indication

**Hepatocellular carcinoma**

Nexavar is indicated for the treatment of hepatocellular carcinoma.

**Renal cell carcinoma**

Nexavar is indicated for the treatment of patients with advanced renal cell carcinoma who have failed prior interferon-alpha or interleukin-2 based therapy or are considered unsuitable for such therapy.

**Differentiated thyroid carcinoma**

Nexavar is indicated for the treatment of patients with progressive, locally advanced or metastatic, differentiated (papillary/follicular/Hürthle cell) thyroid carcinoma, refractory to radioactive iodine.

## Authorisation details

EMA product number EMEA/H/C/000690 Marketing authorisation holder

Bayer AG

51368 Leverkusen

Marketing authorisation issued 19/07/2006 Revision 35

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Nexavar : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (287.32 KB - PDF)

**First published:** 02/12/2009

**Last updated:** 28/03/2025

[View](/en/documents/procedural-steps-after/nexavar-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf)

Nexavar-H-C-690-PSUV-37 : EPAR - Scientific conclusions and grounds recommending the variation to the terms of the marketing authorisation

Reference Number: EMA/754485/2014

English (EN) (60.03 KB - PDF)

**First published:** 20/01/2015

**Last updated:** 20/01/2015

[View](/en/documents/scientific-conclusion/nexavar-h-c-690-psuv-37-epar-scientific-conclusions-and-grounds-recommending-variation-terms-marketing-authorisation_en.pdf)

Nexavar-H-C-690-II-35 : EPAR - Assessment Report - Variation

Adopted

Reference Number: EMA/CHMP/220738/2014

English (EN) (3.09 MB - PDF)

**First published:** 18/06/2014

**Last updated:** 18/06/2014

[View](/en/documents/variation-report/nexavar-h-c-690-ii-35-epar-assessment-report-variation_en.pdf)

CHMP post-authorisation summary of positive opinion for Nexavar

Adopted

Reference Number: EMA/CHMP/236261/2014

English (EN) (61.82 KB - PDF)

**First published:** 25/04/2014

**Last updated:** 25/04/2014

[View](/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-nexavar_en.pdf)

Nexavar-H-C-690-II-05 : EPAR - Scientific Discussion - Variation

Adopted

English (EN) (369.96 KB - PDF)

**First published:** 18/12/2007

**Last updated:** 18/12/2007

[View](/en/documents/scientific-discussion-variation/nexavar-h-c-690-ii-05-epar-scientific-discussion-variation_en.pdf)

## Initial marketing authorisation documents

Nexavar : EPAR - Scientific Discussion

English (EN) (389.83 KB - PDF)

**First published:** 05/03/2007

**Last updated:** 05/03/2007

[View](/en/documents/scientific-discussion/nexavar-epar-scientific-discussion_en.pdf)

Nexavar : EPAR - Procedural steps taken before authorisation

English (EN) (16.13 KB - PDF)

**First published:** 05/03/2007

**Last updated:** 05/03/2007

[View](/en/documents/procedural-steps/nexavar-epar-procedural-steps-taken-authorisation_en.pdf)

#### News on Nexavar

[European Medicines Agency recommends extending use of Nexavar to include treatment of differentiated thyroid cancer](/en/news/european-medicines-agency-recommends-extending-use-nexavar-include-treatment-differentiated-thyroid-cancer) 25/04/2014

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 April 2014](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-april-2014) 25/04/2014

#### Product information - with tracked changes

The approved product information for this medicine is available below showing the changes since the previous procedure affecting the product information. The same document without tracked changes is above under 'Product information'.

Nexavar : EPAR - Product information - tracked changes

English (EN) (113.11 KB - DOCX)

**First published:** 28/03/2025

[View](/en/documents/product-information-tracked-changes/nexavar-epar-product-information-tracked-changes_en.docx)

[Other languages (24)](#file-language-dropdown-712)

български (BG) (128.94 KB - DOCX)

**First published:**

28/03/2025

[View](/bg/documents/product-information-tracked-changes/nexavar-epar-product-information-tracked-changes_bg.docx)

español (ES) (112.19 KB - DOCX)

**First published:**

28/03/2025

[View](/es/documents/product-information-tracked-changes/nexavar-epar-product-information-tracked-changes_es.docx)

čeština (CS) (116.7 KB - DOCX)

**First published:**

28/03/2025

[View](/cs/documents/product-information-tracked-changes/nexavar-epar-product-information-tracked-changes_cs.docx)

dansk (DA) (111.49 KB - DOCX)

**First published:**

28/03/2025

[View](/da/documents/product-information-tracked-changes/nexavar-epar-product-information-tracked-changes_da.docx)

Deutsch (DE) (99.22 KB - DOCX)

**First published:**

28/03/2025

[View](/de/documents/product-information-tracked-changes/nexavar-epar-product-information-tracked-changes_de.docx)

eesti keel (ET) (106.32 KB - DOCX)

**First published:**

28/03/2025

[View](/et/documents/product-information-tracked-changes/nexavar-epar-product-information-tracked-changes_et.docx)

ελληνικά (EL) (114.27 KB - DOCX)

**First published:**

28/03/2025

[View](/el/documents/product-information-tracked-changes/nexavar-epar-product-information-tracked-changes_el.docx)

français (FR) (124.75 KB - DOCX)

**First published:**

28/03/2025

[View](/fr/documents/product-information-tracked-changes/nexavar-epar-product-information-tracked-changes_fr.docx)

hrvatski (HR) (132.69 KB - DOCX)

**First published:**

28/03/2025

[View](/hr/documents/product-information-tracked-changes/nexavar-epar-product-information-tracked-changes_hr.docx)

íslenska (IS) (109.33 KB - DOCX)

**First published:**

28/03/2025

[View](/is/documents/product-information-tracked-changes/nexavar-epar-product-information-tracked-changes_is.docx)

italiano (IT) (116.35 KB - DOCX)

**First published:**

28/03/2025

[View](/it/documents/product-information-tracked-changes/nexavar-epar-product-information-tracked-changes_it.docx)

latviešu valoda (LV) (113.27 KB - DOCX)

**First published:**

28/03/2025

[View](/lv/documents/product-information-tracked-changes/nexavar-epar-product-information-tracked-changes_lv.docx)

lietuvių kalba (LT) (117.39 KB - DOCX)

**First published:**

28/03/2025

[View](/lt/documents/product-information-tracked-changes/nexavar-epar-product-information-tracked-changes_lt.docx)

magyar (HU) (111.52 KB - DOCX)

**First published:**

28/03/2025

[View](/hu/documents/product-information-tracked-changes/nexavar-epar-product-information-tracked-changes_hu.docx)

Malti (MT) (130.68 KB - DOCX)

**First published:**

28/03/2025

[View](/mt/documents/product-information-tracked-changes/nexavar-epar-product-information-tracked-changes_mt.docx)

Nederlands (NL) (111.81 KB - DOCX)

**First published:**

28/03/2025

[View](/nl/documents/product-information-tracked-changes/nexavar-epar-product-information-tracked-changes_nl.docx)

norsk (NO) (107.73 KB - DOCX)

**First published:**

28/03/2025

[View](/no/documents/product-information-tracked-changes/nexavar-epar-product-information-tracked-changes_no.docx)

polski (PL) (116.35 KB - DOCX)

**First published:**

28/03/2025

[View](/pl/documents/product-information-tracked-changes/nexavar-epar-product-information-tracked-changes_pl.docx)

português (PT) (115.06 KB - DOCX)

**First published:**

28/03/2025

[View](/pt/documents/product-information-tracked-changes/nexavar-epar-product-information-tracked-changes_pt.docx)

română (RO) (118.58 KB - DOCX)

**First published:**

28/03/2025

[View](/ro/documents/product-information-tracked-changes/nexavar-epar-product-information-tracked-changes_ro.docx)

slovenčina (SK) (111.06 KB - DOCX)

**First published:**

28/03/2025

[View](/sk/documents/product-information-tracked-changes/nexavar-epar-product-information-tracked-changes_sk.docx)

slovenščina (SL) (131.6 KB - DOCX)

**First published:**

28/03/2025

[View](/sl/documents/product-information-tracked-changes/nexavar-epar-product-information-tracked-changes_sl.docx)

Suomi (FI) (115.3 KB - DOCX)

**First published:**

28/03/2025

[View](/fi/documents/product-information-tracked-changes/nexavar-epar-product-information-tracked-changes_fi.docx)

svenska (SV) (108.28 KB - DOCX)

**First published:**

28/03/2025

[View](/sv/documents/product-information-tracked-changes/nexavar-epar-product-information-tracked-changes_sv.docx)

#### More information on Nexavar

This product was originally designated an orphan medicine for the following orphan indications:

- [treatment of renal cell carcinoma](https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-04-207) (29/07/2004);
- [treatment of hepatocellular carcinoma](https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-06-364) (11/04/2006);
- [treatment of follicular thyroid cancer](https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-13-1199) (13 November 2013);
- [treatment of papillary thyroid cancer](https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-13-1200) (13 November 2013).

The above designations were withdrawn from the Community register of orphan medicinal products in July 2016, November 2017 and May 2024 respectively, at the end of the 10-year period of market exclusivity.

#### More information on Nexavar

- [EMEA-000781-PIP01-09 - paediatric investigation plan](/en/medicines/human/paediatric-investigation-plans/emea-000781-pip01-09)
- [OPTIMIS - Outcomes of HCC patients treated with TACE followed or not followed by sorafenib and the influence of timing to initiate sorafenib - post-authorisation study](https://catalogues.ema.europa.eu/study/26404)
- [RECORA- Regorafenib in patients with metastatic colorectal cancer (mCRC) after failure of standard therapy - post-authorisation study](https://catalogues.ema.europa.eu/study/23329)

#### Topics

- [Medicines](https://www.ema.europa.eu/en/search?f%5B0%5D=ema_search_topics%3A61)

**This page was last updated on** 28/03/2025

## Share this page

[Back to top](#main-content)